Categories: Wire Stories

SemiLEDs to Announce Fiscal Second Quarter 2023 Financial Results on Wednesday, April 12, 2023

HSINCHU, Taiwan–(BUSINESS WIRE)–SemiLEDs Corporation (NASDAQ:LEDS), will report financial results for the 2023 fiscal Second quarter ended February 28, 2023 before market open on Wednesday, April 12, 2023.

About SemiLEDs

SemiLEDs develops, manufactures, and sells LED chips and LED components for general lighting applications, including street lights and commercial, industrial, system and residential lighting, along with specialty industrial applications such as ultraviolet (UV) curing, medical/cosmetic, counterfeit detection, horticulture, architectural lighting and entertainment lighting. SemiLEDs sells blue, white, green and UV LED chips.

Contacts

Christopher Lee

Chief Financial Officer

+886-37-586788

investor@semileds.com

Alex

Recent Posts

Zhengzhou: Interactive Exhibitions on the International Museum Day

ZHENGZHOU, China--(BUSINESS WIRE)--In central China’s Zhengzhou city, visiting museums has become a new trend of…

9 hours ago

Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally

Mollie Pearce, star of the UK reality TV show ‘The Traitors’ who was diagnosed with…

19 hours ago

Quality Building Award 2024 Unveils Finalist List

QBA 2024 Announces 35 Finalists Competing for Hong Kong's Highest Honour in the Building Industry…

2 days ago

UXLINK Tops RootData’s Latest X Hot Items List and DappRadar Social Apps List

SINGAPORE - Media OutReach Newswire - 17 May 2024 - UXLINK, the Web3 social platform…

2 days ago

Australia Construction Industry Report 2024: Growth to Slow to 2% in Real-terms this Year Following 9% Growth in 2023 – Forecasts to 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Australia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to…

2 days ago

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T…

2 days ago